Another Major Drug Approval for Regeneron
Congratulations to BCW member Regeneron on the approval of an important new drug to help patients with rheumatoid arthritis. The U.S. Food and Drug Administration has approved the human antibody drug sarilumab, developed by Regeneron Pharmaceuticals Inc. in Westchester and its French pharmaceutical partner Sanofi and trademarked as Kevzara, to treat adult patients with moderately to severely active rheumatoid arthritis.
The FDA approval came less than two months after the federal agency approved Regeneron’s and Sanofi’s human antibody dupilumab, marketed as Dupixent, as the first biologic medicine used to treat the debilitating itching and widespread rashes afflicting adults with moderate to severe cases of atopic dermatitis.
Similar News Items
Congratulatons to BCW Members Simone Development Companies and Fareri Associates who joined with BCW Member Burke Rehabilitation on Thursday at Purchase Professional Park to celebrate the ribbon cutting of Burke’s expanded Purchase/Fairfield Outpatient Therapy Site at 3020 Westchester Avenue. Elected, business, and clinical leaders from across Westchester and Fairfield counties gathered to tour the state-of-the-art […]
On the September 11 National Day of Service, BCW Member OLA Consulting Engineers teamed up with the Fuller Center for Housing of Greater New York City to help restore a home in Greenburgh that was severely damaged by the remnants of Hurricane Ida in 2021. The entire OLA Consulting Engineers team from the Hawthorne and […]
Anticipating emergency room visits before a patient feels sick and quickly identifying promising clinical trials to treat cancers are among the many benefits of artificial intelligence, according to The Business Council of Westchester’s recent seminar Healing Horizons: Navigating AI in Healthcare’s Transformative Technologies. The September 9 event at Montefiore Einstein Advance Care in Elmsford was […]
Become A Member
Join the county’s largest and most influential business organization today.
JOIN NOW!
Leave a Comment
You must be logged in to post a comment.